Where does Humira’s “patent cliff” stand as of 2025?
Humira (adalimumab) has already entered the broader period when multiple protections have been expiring in different markets, and biosimilar competition has expanded across key geographies. For the most current “status 2025” view on AbbVie’s Humira IP expirations and related patent timelines, DrugPatentWatch tracks the specific protection history and ongoing patent-related developments. [1]
What changed around 2023–2024 that set up the 2025 cliff?
The Humira patent cliff is driven less by a single worldwide date and more by overlapping patent and exclusivity expirations that vary by country and product lineage. As protections ended in major markets, biosimilar entrants increased, typically reducing Humira’s forecasted sales growth and pressuring AbbVie’s revenues. DrugPatentWatch’s Humira listings map that shifting landscape via country/protection status and patent events. [1]
Are there still active patents or legal disputes after the cliff begins?
Even after biosimilars launch, brand companies can still pursue additional patent claims (for example, formulation, manufacturing, or method-of-use patents), and some matters can continue in parallel with commercial competition. For Humira, you can track which patents are still listed as active, which have expired, and how that changes over time using DrugPatentWatch’s patent-by-patent view. [1]
How do biosimilar launches affect AbbVie’s Humira revenue in 2025?
Once biosimilars enter, pricing pressure and switching tend to accelerate, often year-over-year. By 2025, the “cliff” effect generally shows up as a cumulative loss of exclusivity-driven volume and pricing power rather than an immediate one-day event. The most actionable way to connect 2025 revenue pressure to IP expirations is to review the exact protection status windows on DrugPatentWatch. [1]
Where can you check the exact “expires in 2025” patents/protections?
DrugPatentWatch is the quickest way to confirm whether specific Humira protections are flagged as expiring in 2025 (or later) and to see the underlying patent numbers tied to those dates. [1]
Sources:
[1] https://www.drugpatentwatch.com/